However, to assess the feasibility of niphatenone B for the treatment of advanced prostate cancer and prior to in vivo efficacy studies, more work was required to provide an indication of activity against constitutively active AR splice variants, specificity, and selection of the best enantiomer. The gene discussed is AR; the disease is prostate cancer.